Article Text

Download PDFPDF

P60. Microtubule-depolymerising agents used in antibody-drug-conjugates induce anti-tumour immunity by stimulation of dendritic cells
  1. K Martin1,
  2. P Mueller1,
  3. S Theurich2,
  4. S Savic3,
  5. G Terszowski1,
  6. HM Kvasnicka4,
  7. S Dirnhofer3,
  8. DE Speiser5,
  9. M von Bergwelt-Baildon2 and
  10. A Zippelius6
  1. Aff1 grid.410567.1Department of BiomedicineUniversity Hospital Basel Basel Switzerland
  2. Aff2 grid.411097.a000000008852305XDepartment I of Internal Medicine and Cologne Interventional ImmunologyUniversity Hospital Cologne Cologne Germany
  3. Aff3 grid.410567.1Institute of PathologyUniversity Hospital Basel Basel Switzerland
  4. Aff4 grid.7839.50000000419369721Senckenberg Institute of PathologyUniversity of Frankfurt Frankfurt Germany
  5. Aff5 grid.9851.50000000121654204Ludwig Center for Cancer ResearchUniversity of Lausanne Lausanne Switzerland
  6. Aff6 grid.410567.1Department of Biomedicine and Department of Medical OncologyUniversity Hospital Basel Basel Switzerland

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Antibody drug conjugates (ADCs) are emerging as powerful treatment strategies with outstanding target specificity and high therapeutic activity in cancer patients. Brentuximab vedotin represents a first-in-class ADC directed against CD30-positive malignancies. We hypothesised that its sustained clinical responses could be related to the stimulation of an anti-cancer immune response. We here demonstrate that the dolastatin family of microtubule inhibitors, from which the cytotoxic component of brentuximab vedotin is derived, comprises potent inducers of phenotypic and functional DC maturation. In addition to the direct cytotoxic effect on tumour cells, dolastatins efficiently promoted antigen uptake and migration of tumour-resident DCs to tumour-draining lymph nodes. Exposure of murine and human DCs to dolastatins significantly increased their capacity to prime T cells. Underlining the requirement of an intact host immune system for the full therapeutic benefit of dolastatins, the anti-tumour effect was far less pronounced in immune-compromised mice. When combining dolastatins with tumour-antigen-specific vaccination or blockade of the PD-1/PD-L1 and CTLA-4 co-inhibitory pathways, we observed substantial therapeutic synergies. Ultimately, ADCs using dolastatins induce DC homing and activate cellular anti-tumour immune responses in patients. Our data reveal a novel mechanism of action for dolastatins and provide a strong rationale for clinical treatment regimens combining dolastatin-based therapies, such as brentuximab vedotin, with immune-based therapies.